By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – NanoString Technologies today said that it has raised $20 million in a Series D round of financing.

Among the new investors in the firm is GE, through its healthymagination Fund, as well as former Genzyme Chairman and CEO Henri Termeer. All previous investors in the firm, including Clarus Ventures, Draper Fisher Jurvetson, and OVP Venture Partners, also participated in the financing round.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.